AI Science Tracker
EN

Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma

University of Shanghai for Science and Technology; Shanghai Institute for Biomedical and Pharmaceutical Technologies · 27 Sep 2021 · medicine

Discovery

Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma

Source check: Source checked. Not independent scientific confirmation.

Finding: Using gene-expression profiles from 1,447 HCC patients across TCGA, ICGC and GEO, the study quantified immune-cell signatures with ssGSEA and selected four signatures with Cox analyses and random-forest modeling to form ICSscore. The score stratified prognosis in TCGA and two independent cohorts and was associated with treatment-response datasets. These retrospective associations do not show treatment benefit.

Technology: Immune-cell signature score with Cox regression and XGBoost response classifier

Publication: Publication status unspecified in annotation · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The study built an immune-cell signature score using multivariable Cox regression and used XGBoost to classify response associations in HCC datasets; these retrospective associations do not estimate treatment effects.
Test and result
The ICSscore was developed from 1,447 HCC profiles and assessed for risk stratification across TCGA-LIHC and two independent cohorts; treatment-response associations were examined in HCC datasets and other cancer datasets.
Limitation / still unknown
The cohort and treatment-response analyses are retrospective; the reported associations do not establish prospective treatment selection or patient benefit.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.741226/full · https://europepmc.org/article/MED/34675983 · https://pubmed.ncbi.nlm.nih.gov/34646307/

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.